The 6 most recent market catalysts affecting $CLOV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Clover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant corporate catalyst for Clover Health. The better-than-expected Q2 financial results suggest improved operational efficiency and potentially s…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Clover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant corporate catalyst for Clover Health. Better-than-expected financial results, especially coupled with raised future guidance, often signal a …
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Clover Health Investments Raises FY2026 Sales Guidance from $2.810B-$2.920B to $2.920B-$3.000B vs $2.910B Est
Clover Health Investments (CLOV) announced an upward revision to its FY2026 sales guidance, moving from $2.810B-$2.920B to $2.920B-$3.000B. This update is significant as it indicat…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Clover Health Investments Q2 EPS $0.05 Beats $0.03 Estimate, Sales $743.167M Beat $728.267M Estimate
Clover Health Investments (CLOV) announced Q2 earnings of $0.05 per share, significantly surpassing the analyst consensus of $0.03, and marking a substantial turnaround from a loss…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 65
Clover Health Investments shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $4.2 to $5.5.
The maintained 'Buy' rating and increased price target from a reputable firm like Canaccord Genuity acts as a positive catalyst for Clover Health. This signals to the market that t…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5
Canaccord Genuity's analyst Richard Close maintained a 'Buy' rating for Clover Health Investments (CLOV) and raised the price target from $4.2 to $5.5. This action signals increase…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.